🚀 $HUMA Q2 — ADOPTION SURGES ✅ From 5 → 82 VAC-approved hospitals in 3 months 📈 ✅ ECAT listing gives access to 35 Military + 160 VA hospitals 🇺🇸 First U.S. military facility bought & already reordered Symvess™ 🩺 ✅ July sales > entire H1 2025 sales 💥 ✅ Clinical trial

OpenAI & $OSCR 👀

🚨 HUMACYTE: WHEN “OVERVALUED” ACTUALLY MEANS “FULL OF POTENTIAL” Recently, Simply Wall Street published a note suggesting that Humacyte (HUMA) is overvalued, citing a price-to-book (P/B) ratio of 69.4x — far above the biotech industry average of around 2.6x. At first glance,

@unusual_whales These accounts are malicious — they deliberately post fake news just to farm followers. The original quote, “打，奉陪到底；谈，大门敞开。” can easily be correctly translated even by machine translation as: “If you want to fight, we’ll fight to the end; if you want to talk, the

🚨BTIG maintains $HUMA at BUY, trimming target to $6 (from $7). That’s still a +255 % upside from today’s $1.69 level. 📈🫣 BTIG Analyst Ryan Zimmerman remains bullish on Humacyte’s bioengineered vessel (ATEV) platform — a first-in-class regenerative medicine tech — despite

-33%… I guess I bought the dip 😳 PT: $5 after Q4 🚀 $HUMA (Humacyte)

In a highly anticipated press release, Humacyte has announced long-term results from Ukrainian patients treated with Symvess™ acellular tissue engineered vessel-tyod in real-world combat conditions have been published in Oxford Academic’s Military Medicine journal. After up to

🚨 $HUMA raises $60M in an oversubscribed direct offering 🚨 Humacyte priced 28.4M shares + warrants at $2.11 each, bringing in ~$60M gross proceeds. Warrants exercisable in 180 days, expiring 2031. ✅ Positives: • Strong investor demand (oversubscribed) signals confidence. •

Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus. Our mission leads us to investigate and innovate across our bioengineered tissue platform. This is great milestone, and just the start of

🫀 CABG REVOLUTION: HUMACYTE LIGHTS A BEACON OF HOPE 🚨 Humacyte’s CTEV—off-the-shelf grafts that become living vessels—just cleared a key bar: 100% patency at 6 months in primates, with host recellularization and remodeling toward a native artery. Not just “better”—a paradigm

🚨 BIG STEP FOR $HUMA 🚨 Humacyte just published preclinical data in JACC: Basic to Translational Science showing its Coronary Tissue Engineered Vessel (CTEV) stayed 100% patent at 6 months in primates, recellularized with host cells, and remodeled to match native arteries. 👉

“Innovation in CABG has been stagnant for far too long,” said Alan Kypson, MD, FACS, Cardiothoracic Surgeon, UNC REX Hospital. Now there this a new article published in JACC: Basic to Translational Science with preclinical data on the use of the investigational coronary tissue

"That's exactly what's happening." 📈 #humacyte $HUMA

🚨 BREAKING: $OSCR CFO Scott Blackley: ICHRA IS GOING TO BE THE FASTEST SECTOR IN THE INDIVIDUAL MARKET.

🚨 A MESSAGE TO ALL HUMACYTE BEARS - $HUMA - Focusing on ~4 units sold in Q2 ignores that July alone was ~$300k in product sales (~12 units) — more than the entire first half — indicating early acceleration rather than a “glacial” launch. - VAC traction is being misread.

📉 HUMACYTE TARGET CUT TD Cowen lowers $HUMA PT from $5.00 → $3.50 but keeps BUY rating.🔥 Analysts still see upside despite trimmed expectations. #stocks #biotech #humacyte

📉 HUMACYTE PRICE TARGET CUT HC Wainwright lowers $HUMA target from $4 → $3 but keeps BUY rating. 👍 Market takeaway: Confidence in long-term growth remains, but near-term caution. #biotech #stocks #humacyte

🚨 HUMACYTE : CLOSE TO BREAK-EVEN? 6 analysts think Humacyte could stop losing money around 2027 (after one more year of losses). That would mean fast growth from here. 🔥 $HUMA #biotech NFA

#HUMACYTE Q1 VS Q2 - $HUMA 🧐 Don't focus on share price, enjoy the story: 📈 VAC (Value Analysis Committee) approvals Q1 2025: 5 hospitals approved Symvess for purchase. Q2 2025: 82 civilian hospitals now have VAC approval — a huge jump, signaling strong commercial traction.

🚨 BORAL REMAINS BULLISH ON HUMACYTE $HUMA PT: $25 The enthusiasm might be a bit over the top… but it still confirms there’s very strong confidence on certain fronts for Humacyte. 💡 Just for fun: if the stock hit $25, that would be a +942% gain from current levels.